A Phase II Trial of Cetuximab (C225) as Therapy for Recurrent Non-Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2010
At a glance
- Drugs Cetuximab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Oct 2008 Actual end date added as 1 Jun 2005 as reported by ClinicalTrials.gov.
- 01 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.